G. Tsokolas, Charalambos Tossounis, S. Tyradellis, Lorenzo Motta, G. Panos, Theo Empeslidis
{"title":"血管性出血仍是诊断、管理和治疗方面的难题","authors":"G. Tsokolas, Charalambos Tossounis, S. Tyradellis, Lorenzo Motta, G. Panos, Theo Empeslidis","doi":"10.3390/vision8010010","DOIUrl":null,"url":null,"abstract":"Aim: Angioid streaks (ASs) are a rare retinal condition and compromise visual acuity when complicated with choroidal neovascularization (CNV). They represent crack-like dehiscences at the level of the Bruch’s membrane. This objective narrative review aims to provide an overview of pathophysiology, current treatment modalities, and future perspectives on this condition. Materials and Methods: A literature search was performed using “PubMed”, “Web of Science”, “Scopus”, “ScienceDirect”, “Google Scholar”, “medRxiv”, and “bioRxiv.” Results: ASs may be idiopathic, but they are also associated with systemic conditions, such as pseudoxanthoma elasticum, hereditary hemoglobinopathies, or Paget’s disease. Currently, the main treatment is the use of anti-vascular endothelial growth factors (anti-VEGF) to treat secondary CNV, which is the major complication observed in this condition. If CNV is detected and treated promptly, patients with ASs have a good chance of maintaining functional vision. Other treatment modalities have been tried but have shown limited benefit and, therefore, have not managed to be more widely accepted. Conclusion: In summary, although there is no definitive cure yet, the use of anti-VEGF treatment for secondary CNV has provided the opportunity to maintain functional vision in individuals with AS, provided that CNV is detected and treated early.","PeriodicalId":23649,"journal":{"name":"Vision","volume":"60 8","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Angioid Streaks Remain a Challenge in Diagnosis, Management, and Treatment\",\"authors\":\"G. Tsokolas, Charalambos Tossounis, S. Tyradellis, Lorenzo Motta, G. Panos, Theo Empeslidis\",\"doi\":\"10.3390/vision8010010\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: Angioid streaks (ASs) are a rare retinal condition and compromise visual acuity when complicated with choroidal neovascularization (CNV). They represent crack-like dehiscences at the level of the Bruch’s membrane. This objective narrative review aims to provide an overview of pathophysiology, current treatment modalities, and future perspectives on this condition. Materials and Methods: A literature search was performed using “PubMed”, “Web of Science”, “Scopus”, “ScienceDirect”, “Google Scholar”, “medRxiv”, and “bioRxiv.” Results: ASs may be idiopathic, but they are also associated with systemic conditions, such as pseudoxanthoma elasticum, hereditary hemoglobinopathies, or Paget’s disease. Currently, the main treatment is the use of anti-vascular endothelial growth factors (anti-VEGF) to treat secondary CNV, which is the major complication observed in this condition. If CNV is detected and treated promptly, patients with ASs have a good chance of maintaining functional vision. Other treatment modalities have been tried but have shown limited benefit and, therefore, have not managed to be more widely accepted. Conclusion: In summary, although there is no definitive cure yet, the use of anti-VEGF treatment for secondary CNV has provided the opportunity to maintain functional vision in individuals with AS, provided that CNV is detected and treated early.\",\"PeriodicalId\":23649,\"journal\":{\"name\":\"Vision\",\"volume\":\"60 8\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vision\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3390/vision8010010\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vision","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/vision8010010","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的:血管条纹(ASs)是一种罕见的视网膜病变,当并发脉络膜新生血管(CNV)时,会影响视力。它们是布鲁氏膜水平的裂隙样开裂。这篇客观的叙述性综述旨在概述病理生理学、当前的治疗方法以及对这种疾病的未来展望。材料和方法:使用 "PubMed"、"Web of Science"、"Scopus"、"ScienceDirect"、"Google Scholar"、"medRxiv "和 "bioRxiv "进行文献检索。结果:强直性脊柱炎可能是特发性的,但也与全身性疾病有关,如假黄疽弹性瘤、遗传性血红蛋白病或帕吉特氏病。目前,主要的治疗方法是使用抗血管内皮生长因子(anti-VEGF)来治疗继发性 CNV,这是该病症的主要并发症。如果能及时发现并治疗 CNV,强直性脊柱炎患者就有很大机会保持功能性视力。其他治疗方法也曾尝试过,但疗效有限,因此未能被更多人接受。结论总之,虽然目前还没有彻底治愈的方法,但如果能及早发现并治疗继发性 CNV,使用抗血管内皮生长因子治疗为 AS 患者提供了维持功能性视力的机会。
Angioid Streaks Remain a Challenge in Diagnosis, Management, and Treatment
Aim: Angioid streaks (ASs) are a rare retinal condition and compromise visual acuity when complicated with choroidal neovascularization (CNV). They represent crack-like dehiscences at the level of the Bruch’s membrane. This objective narrative review aims to provide an overview of pathophysiology, current treatment modalities, and future perspectives on this condition. Materials and Methods: A literature search was performed using “PubMed”, “Web of Science”, “Scopus”, “ScienceDirect”, “Google Scholar”, “medRxiv”, and “bioRxiv.” Results: ASs may be idiopathic, but they are also associated with systemic conditions, such as pseudoxanthoma elasticum, hereditary hemoglobinopathies, or Paget’s disease. Currently, the main treatment is the use of anti-vascular endothelial growth factors (anti-VEGF) to treat secondary CNV, which is the major complication observed in this condition. If CNV is detected and treated promptly, patients with ASs have a good chance of maintaining functional vision. Other treatment modalities have been tried but have shown limited benefit and, therefore, have not managed to be more widely accepted. Conclusion: In summary, although there is no definitive cure yet, the use of anti-VEGF treatment for secondary CNV has provided the opportunity to maintain functional vision in individuals with AS, provided that CNV is detected and treated early.